Revenue Up 22 per cent, PAT Up 82 per cent
Thyrocare delivered a robust performance in Q2FY26 with consolidated revenue of Rs 216.53 crore, registering a strong 22 per cent year-on-year growth, led by continued momentum in the Pathology segment, which grew 24 per cent YoY. Normalised EBITDA rose sharply by 49 per cent YoY to Rs 75.36 crore, reflecting improved operating leverage, cost efficiencies, and business mix optimisation.
Profit After Tax surged 82 per cent YoY to Rs 47.90 crore, underscoring the company’s focus on profitable growth. Gross margin remained strong at 72 per cent, with an EBITDA margin of 33 per cent. The company continues to maintain a healthy balance sheet, remaining debt-free on a consolidated basis and holding net cash and short-term investments exceeding Rs 190 crore.
In recognition of its strong financial performance and in line with its commitment to shareholder value creation, the Board of Directors has declared an interim dividend of Rs 7 per equity share (of Rs 10 face value each, pre-bonus) with 24-October-2025 as the record date, and approved a bonus issue in the ratio of 2:1, subject to statutory, regulatory, and shareholder approval.
The proposed bonus issue underscores the company’s consistent performance, confidence in its long-term growth trajectory, and commitment to reward shareholders while enhancing stock liquidity and expanding retail participation.
“We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare, coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India,” Rahul Guha, MD and CEO, Thyrocare Technologies.
“We are delighted with Thyrocare’s strong Q2FY26 performance, which reflects the strength of our business fundamentals, disciplined financial management, and the unwavering commitment of our teams. As we mark 25 years of trust and innovation, the bonus share announcement underscores our commitment to our shareholders and investors, and reinforces confidence in our long-term growth journey,” Alok Kumar Jagnani, Group CFO, Thyrocare.
